Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy

Expert Review of Anticancer Therapy

Volumn 17, Issue 1, 2017, Pages 47-59

  Valecha, Gautam Kishore ^a   Vennepureddy, Adarsh ^a   Ibrahim, Uroosa ^a   Safa, Firas ^a   Samra, Bachar ^b   Atallah, Jean Paul ^a  

^a STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

atezolizumab; avelumab; durvalumab; Immunotherapy; nivolumab; non small cell lung cancer; pembrolizumab

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; AVELUMAB; BEVACIZUMAB; BIOLOGICAL MARKER; BMS 936559; CARBOPLATIN; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 INHIBITOR; DOCETAXEL; DURVALUMAB; ERLOTINIB; GEFITINIB; IMMUNE CHECKPOINT INHIBITOR; INFLIXIMAB; IPILIMUMAB; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; NIVOLUMAB; OSIMERTINIB; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; STEROID; TICILIMUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER;

ADVANCED CANCER; ADVERSE DRUG REACTION; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHILL; COLORECTAL CANCER; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; ENDOCRINE DISEASE; EYE TOXICITY; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTHYROIDISM; INFUSION RELATED REACTION; KIDNEY CARCINOMA; KIDNEY DISEASE; LIVER TOXICITY; METASTATIC MELANOMA; NAUSEA; NEUROLOGIC DISEASE; NON SMALL CELL LUNG CANCER; PANCREAS DISEASE; PATIENT SELECTION; PNEUMONIA; PROTEIN EXPRESSION; PRURITUS; REVIEW; RHEUMATIC DISEASE; SKIN DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; METABOLISM; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; PATIENT SELECTION; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85006305816     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1080/14737140.2017.1259574     Document Type: Review

References (65)

1. Siegel RL, Miller KD, Jemal A., Cancer statistics 2016. CA Cancer J Clin. 2016;66(1):7–30.
2. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–1022.
3. Mahmoud SM, Paish EC, Powe DG, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949–1955.
4. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515–548.
5. Seetharamu N. The state of the art in non-small cell lung cancer immunotherapy. Semin Thorac Cardiovasc Surg. 2014;26(1):26–35.
6. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
7. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.
8. Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10(15):5094–5100.
9. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors:safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–3175.
10. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454.
11. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–2012.
12. Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257–265.
13. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135.•• Based on the results of this trial, nivolumab was approved by the US FDA for the treatment of advanced squamous NSCLC that progressed after treatment with platinum based chemotherapy.
14. Borghaei H, Brahmer J, Horn L, et al. P2. 35:nivolumab vs docetaxel in advanced NSCLC:CheckMate 017/057 2-Y update and exploratory cytokine profile analysis:track:immunotherapy. J Thorac Oncol. 2016;11(10):S237–S238.
15. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.•• Based on the results of this trial, nivolumab was approved by the US FDA for the treatment of advanced non-squamous NSCLC that progressed after treatment with platinum-based chemotherapy.
16. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028.•• Based on the promising results of this trial, pembrolizumab received FDA accelerated approval in October 2015 for the treatment of patients with advanced PD-L1-positive squamous or non-squamous cell NSCLC who experience progression of disease on or after standard platinum-based chemotherapy.
17. Hui R, Gandhi L, Carcereny CE, et al. Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro). In:ASCO Annual Meeting Proceedings; 2016 Jun 3–7; Chicago (IL). p. 9026.
18. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial. Lancet. 2016;387(10027):1540–1550.•• An important phase 3 trial with results favoring pembrolizumab over docetaxel in patients with advanced NSCLC. The results indicated that pembrolizumab use was associated with better survival rates, antitumor activity, and safety profile.
19. Garon EB, Herbst RS, Kim D-W, et al. Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%:results from KEYNOTE-010. In:ASCO Annual Meeting Proceedings; 2016 Jun 3–7; Chicago (IL). p. 9024.
20. Brahmer JR, Kim ES, Zhang J, et al. KEYNOTE-024:phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1). In:ASCO Annual Meeting Proceedings; 2015 May 29–Jun 2; Chicago (IL). p. TPS8103.
21. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567.
22. Horn L, Spigel DR, Gettinger SN, et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC):update from a phase Ia study. In:ASCO Annual Meeting Proceedings; 2015 May 29–Jun 2; Chicago (IL). p. 8029.
23. Spigel DR, Chaft JE, Gettinger SN, et al. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC). In:ASCO Annual Meeting Proceedings; 2015 May 29–Jun 2; Chicago (IL). p. 8028.
24. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–1846.•• In this study, atezolizumab met its primary endpoint and showed a statistically significant survival benefit compared to chemotherapy in patients with tumors with higher PD-L1 expression.
25. Besse B, Johnson M, Janne P, et al. 16LBA phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). Eur J Cancer. 2015;51:S717–S718. Available from:http://www.europeancancercongress.org/Scientific-Programme/Abstract-search
26. Rizvi NA, Brahmer JR, Ou S-HI, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). In:ASCO Annual Meeting Proceedings; 2015 May 29–Jun 2; Chicago (IL). p. 8032.
27. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465.
28. Gulley JL, Spigel D, Kelly K, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients:a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. In:ASCO Annual Meeting Proceedings; 2015 May 29–Jun 2; Chicago (IL). p. 8034.
29. Reck M, DeGreen HP, Rose AL, et al. Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer:the phase 3 JAVELIN Lung 100 trial. J Clin Oncol. 2016;34(15 Suppl):TPS9105.
30. Gadgeel S, Stevenson J, Langer C, et al. Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC:KEYNOTE-021 cohorts AC. In 2016 ASCO Annual Meeting;2016 Jun 3–7; Chicago (IL).
31. Sv L, Powderly JD, Camidge DR, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). In:ASCO Annual Meeting Proceedings; 2015 May 29–Jun 2; Chicago (IL). p. 8030.
32. Antonia SJ, Brahmer JR, Gettinger SN, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). In:ASCO Annual Meeting Proceedings; 2014 May 30-Jun 3; Chicago (IL). p. 8113.
33. Gettinger S, Chow LQ, Borghaei H, et al. Safety and response with nivolumab (Anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2014;90(5):S34–S35.
34. Gibbons D, Chow L, Kim D, et al. 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G):a phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC. J Thorac Oncol. 2016;11(4 Suppl):S79.
35. Antonia SJ, Gettinger SN, Chow LQM, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC:interim phase I results. In:ASCO Annual Meeting Proceedings; 2014 May 30–Jun 3; Chicago (IL). p. 8023.
36. Hellmann M, Gettinger S, Goldman J, et al. CheckMate 012:safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. J Clin Oncol. 2016;34. Abstract no:3001.
37. Gubens M, Sequist L, Stevenson J. Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC:KEYNOTE-021 cohorts D and H. J Clin Oncol. 2016;34. Abstract no:9027.
38. Gandhi L, Lubiniecki G, Balmanoukian A, et al. MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC):antitumor activity and association with tumor PD-L1 expression. J Thorac Oncol. 2014;9:S154–S154.
39. Jing W, Li M, Zhang Y, et al. PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. Onco Targets Ther. 2016;9:489–502.
40. Santarpia M, Giovannetti E, Rolfo C, et al. Recent developments in the use of immunotherapy in non-small cell lung cancer. Expert Rev Respir Med. 2016;10(7):781–798.
41. Carbognin L, Pilotto S, Milella M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1):sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One. 2015;10(6):e0130142.
42. Champiat S, Ferté C, Lebel-Binay S, et al. Exomics and immunogenics:bridging mutational load and immune checkpoints efficacy. Oncoimmunology. 2014;3(1):e27817.
43. Shien K, Papadimitrakopoulou VA, Wistuba II. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. Lung Cancer. 2016;99:79–87.
44. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128.
45. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2016;27:1362–1362.
46. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–133.
47. Merrill SP, Reynolds P, Kalra A, et al. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. Ann Pharmacother. 2014;48(6):806–810.
48. Pagès C, Gornet JM, Monsel G, et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res. 2013;23(3):227–230.
49. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60.
50. Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009;361(2):211–212.
51. Izzedine H, Gueutin V, Gharbi C, et al. Kidney injuries related to ipilimumab. Invest New Drugs. 2014;32(4):769–773.
52. Thajudeen B, Madhrira M, Bracamonte E, et al. Ipilimumab granulomatous interstitial nephritis. Am J Ther. 2015;22(3):e84–e87.
53. Forde PM, Rock K, Wilson G, et al. Ipilimumab-induced immune-related renal failure–a case report. Anticancer Res. 2012;32(10):4607–4608.
54. Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control:an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8(1):e53745.
55. Ryder M, Callahan M, Postow MA, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma:a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21(2):371–381.
56. Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98(4):1361–1375.
57. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532.
58. Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037):a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–384.
59. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071):a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–530.
60. Chmiel KD, Suan D, Liddle C, et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol. 2011;29(9):e237–e240.
61. Patnaik A, Socinski MA, Gubens MA, et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC):KEYNOTE-021 cohort D. In:ASCO Annual Meeting Proceedings; 2015 May 29-Jun 2; Chicago (IL). p. 8011.
62. Loochtan AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve. 2015;52(2):307–308.
63. Mandel JJ, Olar A, Aldape KD, et al. Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci. 2014;344(1–2):229–231.
64. Postow MA. Managing immune checkpoint-blocking antibody side effects. Chicago (IL):American Society of Clinical Oncology; 2015.
65. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–319.